DOCSLIB.ORG

Vertebroplasty and Kyphoplasty As Treatment for Osteoporotic Vertebral Fractures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vertebroplasty and Kyphoplasty As Treatment for Osteoporotic Vertebral Fractures ISSN 1889-836X Volume 2 Number 2 July 2010 Revista de Osteoporosis y Metabolismo Mineral EDITORIALS Bone Pathology of Gaucher's Disease 5 López-Herce Cid JA The paradox of vitamin D deficiency in sunny regions, in young people, or in osteoporotic 7 patients treated with vitamin D, could be explained by common genetic variation. Have we found the Rosetta Stone to this apparent contradiction? Quesada Gómez JM ORIGINAL ARTICLES Factors related to vitamin D deficiency in medical students in Gran Canaria 11 Groba Marco MV, Mirallave Pescador A, González Rodríguez E, García Santana S, González Padilla E, Saavedra Santana P et al Effect of zoledronic acid on the markers for bone remodelling in Paget’s disease 21 Díaz Curiel M, Serrano Morales R, De la Piedra Gordo C, Moro Álvarez MJ, Andrade Poveda M Vertebroplasty and kyphoplasty as a treatment for osteoporotic fractures 27 Pérez-Núñez MI, Riancho Moral JA REVIEWS Importance of the type of formulation of the preparations of calcium and vitamin D in the prevention 35 and treatment of osteoporosis García Quetglas E, Urdaneta Abate M, Sádaba Díaz de Rada B, Landecho Acha M, Lucena Ramírez F, Azanza Perea JR Cardiovascular disease, type 2 diabetes and osteoporosis 47 Reyes García R, Rozas Moreno P, Muñoz Torres M Determining the principal metabolites of vitamin D in the blood through on-line solid phase 55 extraction with liquid chromatography-mass spectrometry in tandem Mata-Granados JM, Ferreiro-Verab C, Luque de Castro MD, Quesada Gómez JM SPECIAL DOCUMENTS Current perspectives on the role of vitamin D and calcium in the patient care for osteoporosis: 63 An expert panel discussion Jódar Gimeno E, González Macías J, Aguado Acín P, Quesada Gómez JM, Cáceres E, Nocea G Consensual conclusions of the I Multidisciplinary Forum on the management of patients with High 79 Risk of osteoporotic Fracture (HRF) Jódar Gimeno E and members of the Scientific Committee and participants in the I Multidisciplinary Forum on the management of patients with High Risk of osteoporotic Fracture LETTER TO THE EDITOR Codification of hip fractures 89 Sosa Henríquez M, de Miguel Ruiz E, Arbelo Rodríguez A, Rodríguez Hernández A, García Bravo A www.revistadeosteoporosisymetabolismomineral.com Revista de Osteoporosis y Metabolismo Mineral Director Editing Manuel Sosa Henríquez Ibáñez & Plaza Asociados, S. L. Editor Head EDITORIAL TÉCNICA Y COMUNICACIÓN Mª Jesús Gómez de Tejada Romero Avda. Reina Victoria, 47 (6º D) 28003 Madrid Telf./Fax 915 537 462 Sociedad Española de Investigación Ósea e-mail: [email protected] y del Metabolismo Mineral (SEIOMM) http://www.ibanezyplaza.com President Graphic design Manuel Sosa Henríquez Concha García García Vice-president English translation Javier del Pino Montes Andrew Stephens Treasurer Impresion Esteban Jódar Gimeno Imprenta Narcea Secretariat SVP Mª Jesús Gómez de Tejada Romero 32/09-R-CM Legal deposit Avda. Capitán Haya, 60 (1ª planta) AS-4777-09 28020 Madrid (Spain) ISSN 1889-836X Telf: +34-917499512 Fax: +34-915708911 e-mail: [email protected] http://www.seiomm.org E-mail: [email protected] On-line version: http://www.revistadeosteoporosisymetabolismomineral.com Committee of experts Pilar Aguado Acín Adolfo Díez Pérez Pau Lluch Mezquida Concepción de la Piedra Gordo Javier Alegre López Casimira Domínguez Cabrera José Andrés López-Herce Cid Javier del Pino Montes María José Amérigo García Anna Enjuanes Guardiola Carlos Lozano Tonkin José Manuel Quesada Gómez Abdón Arbelo Rodríguez Pedro Esbrit Argüelles Mª Luisa Mariñoso Barba Enrique Raya Álvarez Miguel Arias Paciencia Fernando Escobar Jiménez Guillermo Martínez Díaz-Guerra Rebeca Reyes García Emilia Aznar Villacampa Jordi Farrerons Minguella Julio Medina Luezas José Antonio Riancho del Corral Chesús Beltrán Audera José Filgueira Rubio Leonardo Mellivobsky Saldier Luis de Rio Barquero Pere Benito Ruiz Jordi Fiter Areste Manuel Mesa Ramos Luis Rodríguez Arboleya Santiago Benito Urbina Juan José García Borrás Pedro Mezquita Raya Minerva Rodríguez García Miguel Bernard Pineda Sergio García Pérez Ana Monegal Brancos Antonia Rodríguez Hernández Pedro Betancor León Juan Alberto García Vadillo Josefa Montoya García Manuel Rodríguez Pérez Josep Blanch i Rubió Eduardo Girona Quesada María Jesús Moro Álvarez Montaña Román García José Antonio Blázquez Cabrera Carlos Gómez Alonso Manuel Muñoz Torres Inmaculada Ros Villamajó Javier Calvo Catalá Mª Jesús Gómez de Tejada Romero Laura Navarro Casado Rafael Sánchez Borrego Mª Jesús Cancelo Hidalgo Jesús González Macías Manuel Naves García Armando Torres Ramírez Jorge Cannata Andía Emilio González Reimers José Luis Neyro Bilbao Antonio Torrijos Eslava Antonio Cano Sánchez Jenaro Graña Gil Xavier Nogués i Solán Carmen Valdés y Llorca Cristina Carbonell Abella Silvana di Gregorio Joan Miquel Nolla Solé Carmen Valero Díaz de Lamadrid Jordi Carbonell Abelló Daniel Grinberg Vaisman José Antonio Olmos Martínez Ana Weruaga Rey Pedro Carpintero Benítez Nuria Guañabens Gay Norberto Ortego Centeno Jaime Zubieta Tabernero Enrique Casado Burgos Federico Hawkins Carranza Santiago Palacios Gil-Antuñano Santos Castañeda Sanz Diego Hernández Hernández Esteban Pérez Alonso METHODOLOGY AND DESIGN OF DATA Fidencio Cons Molina José Luis Hernández Hernández Ramón Pérez Cano Pedro Saavedra Santana Sonia Dapia Robleda Gabriel Herrero-Beaumont Cuenca José Luis Pérez Castrillón José María Limiñana Cañal Manuel Díaz Curiel Esteban Jódar Gimeno Luis Pérez Edo Bernardino Díaz López Fernando Lecanda Cordero Pilar Peris Bernal ISSN 1889-836X Volume 2 Number 2 July 2010 Revista de Osteoporosis y Metabolismo Mineral Cardiovascular disease, type 2 diabetes EDITORIALS 47 and osteoporosis 5 Bone Pathology of Gaucher's Disease Reyes García R, Rozas Moreno P, Muñoz López-Herce Cid JA Torres M The paradox of vitamin D deficiency Determining the principal metabolites of 7 in sunny regions, in young people, or in 55 vitamin D in the blood through on-line osteoporotic patients treated with vitamin solid phase extraction with liquid chro- D, could be explained by common gene- matography-mass spectrometry in tan- tic variation. Have we found the Rosetta dem Stone to this apparent contradiction? Mata-Granados JM, Ferreiro-Verab C, Quesada Gómez JM Luque de Castro MD, Quesada Gómez JM ORIGINAL ARTICLES SPECIAL DOCUMENTS 11 Factors related to vitamin D deficiency in medical students in Gran Canaria 63 Current perspectives on the role of vita- Groba Marco MV, Mirallave Pescador A, min D and calcium in the patient care for González Rodríguez E, García Santana S, osteoporosis: An expert panel discussion González Padilla E, Saavedra Santana P Jódar Gimeno E, González Macías J, et al Aguado Acín P, Quesada Gómez JM, Cáceres E, Nocea G Effect of zoledronic acid on the markers 21 for bone remodelling in Paget’s disease Consensual conclusions of the I Díaz Curiel M, Serrano Morales R, De la 79 Multidisciplinary Forum on the manage- Piedra Gordo C, Moro Alvarez MJ, ment of patients with High Risk of osteo- Andrade Poveda M porotic Fracture (HRF) Jódar Gimeno E and members of the Vertebroplasty and kyphoplasty as a tre- Scientific Committee and participants in 27 atment for osteoporotic fractures the I Multidisciplinary Forum on the Pérez-Núñez MI, Riancho Moral JA management of patients with High Risk of osteoporotic Fracture REVIEWS LETTER TO THE EDITOR 35 Importance of the type of formulation of the preparations of calcium and vitamin D 89 Codification of hip fractures in the prevention and treatment of osteo- Sosa Henríquez M, de Miguel Ruiz E, porosis Arbelo Rodríguez A, Rodríguez García Quetglas E, Urdaneta Abate M, Hernández A, García Bravo A Sádaba Díaz de Rada B, Landecho Acha M, Lucena Ramírez F, Azanza Perea JR Reviewers who have participa- Jordi Fiter Arese José Olmos Martínez ted in volume 2 (numbers 1-2) Juan José García Borrás Ramón Pérez Cano Pilar Aguado Acín Mª Jesús Gómez de Tejada Romero Concha de la Piedra Gordo Luis Arboleya Rodríguez Nuria Guañabens Gay Javier del Pino Montes Josep Blanch i Rubió José Luis Hernández Jose Manuel Quesada Gómez José Ramón Caeiro Rey Esteban Jódar Gimeno Luis del Río Barquero Pedro Carpintero Benítez Pedro Mezquita Raya Manuel Sosa Henríquez Manuel Díaz Curiel Manuel Muñoz Torres Carmen Valero Díaz de Lamadrid Bernardino Díaz López Xavier Nogués Solán EDITORIALS / Rev Osteoporos Metab Miner 2010 2;2:5-6 5 Bone pathology of Gaucher disease López-Herce Cid JA Servicio de Medicina Interna - Hospital General Universitario Gregorio Marañón - Madrid (Spain) e-mail: [email protected] aucher disease (GD) is a congenital mia, thrombopenia, haemorrhages, delayed fault of the metabolism due to a growth, hepatomegaly, splenomegaly and changes deficiency in the lysosomal enzyme in liver function tests. The prognosis of GD glucocerebrosidase, also called acid depends on the degree of affectation of these cli- beta glucosidase. This enzyme defi- nical manifestations. GD is a disease which starts cit results in the accumulation of in infancy but which is not usually diagnosed until G non-metabolised substrate in the the age of 16 years2. Even in those patients diagno- lysosomes of various cell lines of sed as adults, the signs and symptoms begin in the monocyte-macrophage system. The deposit of infancy3. This is why each patient is different in non-degraded material, a glucocerebroside called terms their age of presentation, symptomology, glucosylceramide, is an intermediate metabolite in diagnosis and progression of the disease. the synthesis and breakdown
Load more

Recommended publications
  • Efficacy and Safety of Elcatonin in Postmenopausal Women with Osteoporosis: a Systematic Review with Network Meta-Analysis of Randomized Clinical Trials
    Osteoporosis International (2019) 30:1723–1732 https://doi.org/10.1007/s00198-019-04997-6 REVIEW Efficacy and safety of elcatonin in postmenopausal women with osteoporosis: a systematic review with network meta-analysis of randomized clinical trials W.-C. Chen1,2 & E.-Y. Lin3 & Y.-N. Kang1,4 Received: 20 November 2018 /Accepted: 21 April 2019 /Published online: 1 May 2019 # International Osteoporosis Foundation and National Osteoporosis Foundation 2019 Abstract Summary The present systematic review aimed to evaluate bone mineral density (BMD) change and complication rates of elcatonin on treating postmenopausal osteoporosis. The result confirmed efficacy of elcatonin and safety in combination thera- pies of elcatonin (C-E). Introduction Postmenopausal osteoporosis is an important issue in global aging trends. One treatment of osteoporosis is elcatonin, a kind of calcitonin. However, it has been challenged for long time because of safety. Many trials investigated on this topic, but they were designed differently. Those designs can be categorized in monotherapy of elcatonin (M-E) and C-E. Unfortunately, no synthesized evidence dealt this topic. Methods This study systematically identified target trials from six important databases and only included randomized controlled trial for synthesis. Two investigators assessed quality of eligible trials using the Cochrane Risk of Bias Tool, and they indepen- dently extracted data. Network meta-analysis performed Peto odds ratio (POR, used for dealing with zero cell) or weighted mean difference (WMD, for continuous data) with 95% confidence intervals (CI) and consistency H. Results Sixteen trials recruiting 2754 women with postmenopausal osteoporosis were included in our study. Elcatonin therapies and non-elcatonin medications had comparable fracture rates and bone mineral density change.
    [Show full text]
  • 1 Advances in Therapeutic Peptides Targeting G Protein-Coupled
    Advances in therapeutic peptides targeting G protein-coupled receptors Anthony P. Davenport1Ϯ Conor C.G. Scully2Ϯ, Chris de Graaf2, Alastair J. H. Brown2 and Janet J. Maguire1 1Experimental Medicine and Immunotherapeutics, Addenbrooke’s Hospital, University of Cambridge, CB2 0QQ, UK 2Sosei Heptares, Granta Park, Cambridge, CB21 6DG, UK. Ϯ Contributed equally Correspondence to Anthony P. Davenport email: [email protected] Abstract Dysregulation of peptide-activated pathways causes a range of diseases, fostering the discovery and clinical development of peptide drugs. Many endogenous peptides activate G protein-coupled receptors (GPCRs) — nearly fifty GPCR peptide drugs have been approved to date, most of them for metabolic disease or oncology, and more than 10 potentially first- in-class peptide therapeutics are in the pipeline. The majority of existing peptide therapeutics are agonists, which reflects the currently dominant strategy of modifying the endogenous peptide sequence of ligands for peptide-binding GPCRs. Increasingly, novel strategies are being employed to develop both agonists and antagonists, and both to introduce chemical novelty and improve drug-like properties. Pharmacodynamic improvements are evolving to bias ligands to activate specific downstream signalling pathways in order to optimise efficacy and reduce side effects. In pharmacokinetics, modifications that increase plasma-half life have been revolutionary. Here, we discuss the current status of peptide drugs targeting GPCRs, with a focus on evolving strategies to improve pharmacokinetic and pharmacodynamic properties. Introduction G protein-coupled receptors (GPCRs) mediate a wide range of signalling processes and are targeted by one third of drugs in clinical use1. Although most GPCR-targeting therapeutics are small molecules2, the endogenous ligands for many GPCRs are peptides (comprising 50 or fewer amino acids), which suggests that this class of molecule could be therapeutically useful.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • Elcatonin (Rinn) Sensitivity Reactions, Including Anaphylaxis, Have Pression of the Airway Or Vulnerable Neurological Structures
    Bone Morphogenetic Proteins/Calcitonins 1093 ports of swelling of neck and throat tissue, with resultant com- Elcatonin (rINN) sensitivity reactions, including anaphylaxis, have pression of the airway or vulnerable neurological structures. [Aminosuberic Acid 1,7]-eel Calcitonin; [Asu1,7]-E-CT; Carbocal- occurred. Complications were often life-threatening, and had required res- piratory support and/or tracheotomy in some cases. The use of citonin; Elcatonina; Elcatonine; Elcatoninum. 1-Butyric acid-7-(L- Calcitonin has inhibited lactation in animals. alternative treatments or enrollment in approved clinical studies 2-aminobutyric acid)-26-L-aspartic acid-27-L-valine-29-L-alanine- Nausea and vomiting may be reduced by giving doses 1 calcitonin (salmon). was recommended when treating cervical spine problems. at bedtime or by giving an antiemetic beforehand. 1. FDA. FDA Public Health Notification: Life-threatening compli- Элькатонин cations associated with recombinant human bone morphogenetic Calcitonin (pork) may contain trace amounts of thyroid C148H244N42O47 = 3363.8. protein in cervical spine fusion. Available at: http:// CAS — 60731-46-6. hormones, but clinical effects are unlikely in most pa- www.fda.gov/cdrh/safety/070108-rhbmp.html (accessed 17/07/08) ATC — H05BA04. tients. ATC Vet — QH05BA04. Preparations Antibody formation. Long-term treatment with heterologous Description. Elcatonin is a synthetic analogue of eel calcitonin. calcitonins may lead to the formation of neutralising antibodies. Proprietary Preparations (details are given in Part 3) Pharmacopoeias. In Jpn. This appears to be common in patients given calcitonin (pork) or, Belg.: InductOs; Cz.: InductOs; Osigraft; Denm.: InductOs; Osigraft; Fin.: to a lesser extent, calcitonin (salmon). Calcitonin (human) is less InductOs; Gr.: InductOs; Osigraft; Irl.: InductOs; Ital.: Osigraft; Neth.: Os- 1 igraft; Norw.: InductOs; Port.: Osigraft; Spain: InductOs; Osigraft; Swed.: Incompatibility.
    [Show full text]
  • Raloxifene Or Calcitonin
    Appendices Table of Contents Appendix A. Search Strategy ................................................................................................... A-1 Appendix B. Risk of Bias Assessment Decision Aid .............................................................. B-1 Appendix C. Included References Risk of Bias Assessment ................................................. C-1 Appendix D. Evidence Tables .................................................................................................. D-1 Table D1. Characteristics of observational studies with low or medium risk of bias ............ D-1 Table D2. Characteristics of RCTs and CCTs with low or medium risk of bias .................... D-6 Table D3. Key Questions 1 & 2 Evidence Overview ........................................................... D-15 Table D4. Key Questions 3 & 4 Evidence Overview ........................................................... D-28 Table D5. Key Questions 5 & 6 Evidence Overview ........................................................... D-45 Table D6. Key Questions 7 & 8 Evidence Overview ........................................................... D-50 Table D7. Characteristics of eligible studies with high risk of bias ..................................... D-52 Strength of Evidence Tables ..................................................................................................... 57 Alendronate ....................................................................................................................... D-57 Table D8.
    [Show full text]
  • Use of Serotonin Reuptake Inhibitors and Risk of Subsequent Bone Loss In
    www.nature.com/scientificreports OPEN Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population‑based cohort study Sunyoung Kang1,6, Minkyung Han2,6, Chun Il Park3, Inkyung Jung4, Eun Hwa Kim2, Young Jun Boo1, Jee In Kang1,5* & Se Joo Kim1,5* This study examined whether the use of SRIs is associated with an increased risk of bone loss using a nested case–control design with a nationwide population–based cohort in Korea. Using the Korean National Health Screening Cohort, subjects newly diagnosed with osteoporosis or osteopenia (n = 55,799) were matched with controls (n = 278,995) at a ratio of 1:5. We stratifed the participants by their time‑dependent use of SRIs and sex and controlled for various confounders, including lifestyle habits, laboratory data, and comorbidities. Conditional logistic regression showed that both recent and former users of SRIs had an increased risk of subsequent bone loss compared with non‑users: men [recent users: odds ratio (OR) 1.35, 95% confdential interval (CI) 1.20, 1.53; former‑users: OR 1.10, 95% CI 1.01, 1.20]; women (recent users: OR 1.38, 95% CI 1.28–1.48; former‑users: OR 1.07, 95% CI 1.02, 1.21). The use of SRIs was associated with an increased risk of bone loss in both men and women. In particular, the association was stronger in recent users. These fndings provide population‑ level evidence for the risk of bone loss associated with SRI exposure and highlight the importance of monitoring the bone health of SRI users.
    [Show full text]
  • Pharmacological Study of Teriparatide on Ovariectomy-Induced Hyperalgesia in Rats
    Title Pharmacological study of teriparatide on ovariectomy-induced hyperalgesia in rats Author(s) 田中, 智哉 Citation 北海道大学. 博士(歯学) 甲第13876号 Issue Date 2020-03-25 DOI 10.14943/doctoral.k13876 Doc URL http://hdl.handle.net/2115/78480 Type theses (doctoral) File Information Tomoya_Tanaka.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP 博 士 論 文 Pharmacological study of teriparatide on ovariectomy-induced hyperalgesia in rats （卵巣摘除ラットモデルを用いた骨粗鬆性痛覚過 敏に対するテリパラチドの薬理作用の解明） 令和 2 年 3 月申請 北海道大学 大学院歯学研究科口腔医学専攻 田 中 智 哉 目次 Introduction .................................................................................................................. 3 Materials and methods ................................................................................................ 4 Experimental animals ....................................................................................................................4 Experimental design ......................................................................................................................4 Pain-related behavioral test ...........................................................................................................5 Plantar test ................................................................................................................................. 5 von Frey test ..............................................................................................................................6 Skeletal analyses ...........................................................................................................................6
    [Show full text]
  • Supplement Ii to the Japanese Pharmacopoeia Seventeenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION O‹cial from June 28, 2019 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. Printed in Japan The Ministry of Health, Labour and Welfare Ministerial Notification No. 49 Pursuant to Paragraph 1, Article 41 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145, 1960), this notification stated that a part of the Japanese Pharmacopoeia was revised as follows*. NEMOTO Takumi The Minister of Health, Labour and Welfare June 28, 2019 A part of the Japanese Pharmacopoeia (Ministerial Notification No. 64, 2016) was revised as follows*. (The text referred to by the term ``as follows'' are omitted here. All of the revised Japanese Pharmacopoeia in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'' in Supplement 2) are made available for public exhibition at the Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmen- tal Health Bureau, Ministry of Health, Labour and Welfare, at each Regional Bureau of Health and Welfare, and at each Prefectural Office in Japan). Supplementary Provisions (Effective Date) Article 1 This Notification is applied from June 28, 2019. (Transitional measures) Article 2 In the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as ``previous Pharmacopoeia'') [limited to those listed in new Pharmacopoeia] and drugs which have been approved as of June 28, 2019 as prescribed under Paragraph 1, Article 14 of Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Orphan Drug Designation List
    Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 1 (-)-(3aR,4S,7aR)-4-Hydroxy-4- m-tolylethynyl-octahydro- Novartis indole-1-carboxylic acid Pharmaceuticals methyl ester n/a 10/12/2011 Treatment of Fragile X syndrome Corp. 2 (1-methyl-2-nitro-1H- imidazole-5-yl)methyl N,N'- bis(2-broethyl) diamidophosphate n/a 6/5/2013 Treatment of pancreatic cancer EMD Serono 3 (1-methyl-2-nitro-1H- imidazole-5-yl)methyl N,N'- bis(2-bromoethyl) Threshold diamidophosphate n/a 3/9/2012 Treatment of soft tissue sarcoma Pharmaceuticals, Inc. 4 (1OR)-7-amino-12-fluoro- 2,10,16-trimethyl-15 oxo- 10,15,16,17-tetrahydro-2H-8,4- Treatment of anaplastic (metheno)pyrazolo[4,3- lymphoma kinase (ALK)-positive h][2,5,11]benzoxadiazacyclote or ROS1-positive non-small cell tradecine-3-carbonitrile n/a 6/23/2015 lung cancer Pfizer, Inc. 5 (1R,3R,4R,5S)-3-O-[2-O- Treatment of vaso-occlusive benzoyl-3-O-(sodium(2S)-3- crisis in patients with sickle cell cyclohexyl-propanoate- n/a 2/17/2009 disease. Pfizer, Inc. 6 (1S)-1-(9-deazahypoxanthin-9- yl)-1,4-dideoxy-1,4-imino-D- Treatment of T-cell non- Mundipharma ribitol-hydrochloride n/a 1/29/2004 Hodgkin's lymphoma Research Limited 7 (1S)-1-(9-deazahypoxanthin-9- yl)-1,4-dideoxy-1,4-imino-D- Treatment of acute Mundipharma ribitol-hydrochloride n/a 8/13/2004 lymphoblastic leukemia Research Limited Page 1 of 364 Orphan Drug Designations and Approvals List as of 06‐01‐2016 Governs July 1, 2016 ‐ September 30, 2016 Row Contact Generic Name Trade Name Designation Date Designation Num Company/Sponsor 8 Treatment of chronic lymphocytic leukemia and related leukemias to include (1S)-1-(9-deazahypoxanthin-9- prolymphocytic leukemia, adult T- yl)-1,4-dideoxy-1,4-imino-D- cell leukemia, and hairy cell Mundipharma ribitol-hydrochloride n/a 8/10/2004 leukemia Research Ltd.
    [Show full text]
  • Product List
    PRODUCT LIST Active Pharma Ingredients API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document A Acotiamide Hydrochloride - 773092-05-0 - Almagate EP 66827-12-1 - Aluminum Hydroxide BP, USP 21645-51-2 - C Cimetidine - 51481-61-9 - D Dexlansoprazole - 138530-94-6 - Dexlansoprazole - 313640-86-7 DMF Sesquihydrate Dexrabeprazole Sodium - 171440-18-9 ODMF, Tech Pack E Ecabet Sodium - 86408-72-2 DMF Esomeprazole - 119141-88-7 - Esomeprazole Magneisum - 217087-10-0 - Dihydrate Esomeprazole Magnesium - 161973-10-0 - Esomeprazole Magnesium USP 217087-09-7 CEP, DMF Trihydrate Esomeprazole Potassium IHS 161796-84-5 DMF Esomeprazole Sodium - 161796-78-7 - Esomeprazole Zinc/ 793668-08-3, - - Base/Strontium 119141-88-7 F Famotidine - 76824-35-6 - E Glycopyrrolate - 596-51-0 - H Hydrotelcite BP 12304-65-3 - I Ilaprazole IHS, IP 172152-36-2 DMF Ilaprazole Sodium - 172152-50-0 ODMF, Tech Pack Itopride - 122898-67-3 - Itopride Hydrochloride IHS 122892-31-3 - Patent Disclaimer: Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. 2021-01-11 © ExSyn Corp | All rights reserved. | www.exsyncorp.com 1 API Acid Reflux Disorders Product Pharmacopoeia CAS No. Technical Document L Lafutidine - 118288-08-7 - Lansoprazole - 103577-45-3 - Lansoprazole Sodium - 226904-00-3 - M Magaldrate USP 74978-16-8
    [Show full text]